Find Natalizumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0INTERMEDIATES

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 106128-89-6, Chembl106124, (5s,8s,14s,17s,20s)-14,17-dibenzyl-5-carbamoyl-20-(carboxymethyl)-8-isobutyl-15-methyl-7,10,13,16,19,22-hexaoxo-2-thia-6,9,12,15,18,21-hexaazapentacosan-25-oic acid, Succinyl-6-asp-8-me-phe-substance p (6-11), Substance p (6-11), succinyl-asp(6)-me-phe(8)-, Substance p (6-11), succinyl-aspartyl(6)-methylphenylalanine(8)-
Molecular Formula
C40H55N7O11S
Molecular Weight
842.0  g/mol
InChI Key
HMHYXLVEFVGOPM-QKUYTOGTSA-N

Natalizumab
1 2D Structure

Natalizumab

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S)-4-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutanoic acid
2.1.2 InChI
InChI=1S/C40H55N7O11S/c1-24(2)19-28(37(55)45-27(36(41)54)17-18-59-4)44-33(49)23-42-39(57)31(21-26-13-9-6-10-14-26)47(3)40(58)30(20-25-11-7-5-8-12-25)46-38(56)29(22-35(52)53)43-32(48)15-16-34(50)51/h5-14,24,27-31H,15-23H2,1-4H3,(H2,41,54)(H,42,57)(H,43,48)(H,44,49)(H,45,55)(H,46,56)(H,50,51)(H,52,53)/t27-,28-,29-,30-,31-/m0/s1
2.1.3 InChI Key
HMHYXLVEFVGOPM-QKUYTOGTSA-N
2.1.4 Canonical SMILES
CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(CC1=CC=CC=C1)N(C)C(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(=O)O)NC(=O)CCC(=O)O
2.1.5 Isomeric SMILES
CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@H](CC1=CC=CC=C1)N(C)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Substance P (6-11), Succinyl-asp(6)-me-phe(8)-

2. Substance P (6-11), Succinyl-aspartyl(6)-methylphenylalanine(8)-

3. Succinyl-6-asp-8-me-phe-substance P (6-11)

2.2.2 Depositor-Supplied Synonyms

1. 106128-89-6

2. Chembl106124

3. (5s,8s,14s,17s,20s)-14,17-dibenzyl-5-carbamoyl-20-(carboxymethyl)-8-isobutyl-15-methyl-7,10,13,16,19,22-hexaoxo-2-thia-6,9,12,15,18,21-hexaazapentacosan-25-oic Acid

4. Succinyl-6-asp-8-me-phe-substance P (6-11)

5. Substance P (6-11), Succinyl-asp(6)-me-phe(8)-

6. Substance P (6-11), Succinyl-aspartyl(6)-methylphenylalanine(8)-

7. Gtpl2127

8. Schembl5238634

9. Dtxsid80909926

10. Suc[asp6,mephe3]sp(6-11)

11. Hy-p0187

12. Suc[asp6,mephe3]sp(6-11))

13. Bdbm50052524

14. Mfcd00076799

15. Zinc95615286

16. Cs-8091

17. (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[(4-hydroxy-4-oxobutanoyl)amino]-4-oxobutanoic Acid

18. 4-10-neuromedin B (swine Spinal Cord), N-(3-carboxy-1-oxopropyl)-6-(n-methyl-l-phenylalanine)-7-de-l-valine-

19. L-methioninamide, N-(3-carboxy-1-oxopropyl)-l-alpha-aspartyl-l-phenylalanyl-n-methyl-l-phenylalanylglycyl-l-leucyl-

20. N-(3-carboxy-1-oxopropyl)-6-(n-methyl-l-phenylalanine)-7-de-l-valine-4-10-neuromedin B (swine Spinal Cord)

21. B6580

22. A16945

23. Succinyl-(asp6,n-me-phe8)-substance P (6-11)

24. J-001543

25. Q27088780

26. (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutanoic Acid

27. (s)-n-((s)-1-{[(s)-1-({[(s)-1-((s)-1-carbamoyl-3-methylsulfanyl-propylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-carbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-phenyl-ethyl)-3-(3-carboxy-propionylamino)-succinamic Acid

28. 4-({14-benzyl-7,10,13-trihydroxy-5-[hydroxy(imino)methyl]-15-methyl-8-(2-methylpropyl)-16-oxo-18-phenyl-2-thia-6,9,12,15-tetraazaoctadeca-6,9,12-trien-17-yl}imino)-3-[(3-carboxy-1-hydroxypropylidene)amino]-4-hydroxybutanoic Acid

2.3 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 842.0 g/mol
Molecular Formula C40H55N7O11S
XLogP31.1
Hydrogen Bond Donor Count8
Hydrogen Bond Acceptor Count12
Rotatable Bond Count26
Exact Mass841.36802677 g/mol
Monoisotopic Mass841.36802677 g/mol
Topological Polar Surface Area309 Ų
Heavy Atom Count59
Formal Charge0
Complexity1450
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
SupplySide West 2024
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

NATALIZUMAB

Brand Name : TYSABRI

Dosage Form : VIAL; SINGLE-USE

Dosage Strength : 300MG

Packaging :

Approval Date :

Application Number : 125104

Regulatory Info :

Registration Country : USA

blank

02

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

natalizumab

Brand Name : Tysabri

Dosage Form : CONCENTRATE FOR SOLUTION FOR INFUSION

Dosage Strength : 300 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

03

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Natalizumabum

Brand Name : Tysabri

Dosage Form : Inf Conc

Dosage Strength : 300mg/15ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

04

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Natalizumabum

Brand Name : Tysabri

Dosage Form : Inj L?s

Dosage Strength : 150mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

05

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

NATALIZUMAB

Brand Name : TYSABRI

Dosage Form : SOLUTION

Dosage Strength : 300MG/15ML

Packaging : 1VIAL

Approval Date :

Application Number : 2286386

Regulatory Info : Prescription

Registration Country : Canada

blank

06

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

natalizumab

Brand Name : Tysabri

Dosage Form :

Dosage Strength :

Packaging : 2

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

07

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

natalizumab

Brand Name : Tysabri

Dosage Form :

Dosage Strength :

Packaging : 2

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

08

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

natalizumab

Brand Name : Tysabri

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

09

Biogen

U.S.A
SupplySide West 2024
Not Confirmed
arrow

Biogen

U.S.A
arrow
SupplySide West 2024
Not Confirmed

natalizumab

Brand Name : Tysabri

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank

10

Sandoz B2B

Switzerland
SupplySide West 2024
Not Confirmed
arrow

Sandoz B2B

Switzerland
arrow
SupplySide West 2024
Not Confirmed

NATALIZUMAB-SZTN

Brand Name : TYRUKO

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 300MG/15ML(20MG/ML)

Packaging :

Approval Date :

Application Number : 761322

Regulatory Info :

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty